These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 20954799)

  • 1. Oxidative pathways as a drug target for the treatment of autism.
    Villagonzalo KA; Dodd S; Dean O; Gray K; Tonge B; Berk M
    Expert Opin Ther Targets; 2010 Dec; 14(12):1301-10. PubMed ID: 20954799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxidative stress in autism.
    McGinnis WR
    Altern Ther Health Med; 2004; 10(6):22-36; quiz 37, 92. PubMed ID: 15624347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidative stress in autism.
    McGinnis WR
    Altern Ther Health Med; 2005; 11(1):19. PubMed ID: 15712760
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacological interventions in autism: theoretical and practical issues.
    Volkmar FR
    J Clin Child Psychol; 2001 Mar; 30(1):80-7. PubMed ID: 11294081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Review of psychopharmacological treatments in adolescents and adults with autistic disorders].
    Baghdadli A; Gonnier V; Aussilloux C
    Encephale; 2002; 28(3 Pt 1):248-54. PubMed ID: 12091786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Sixty years of autism].
    van Berckelaer-Onnes IA
    Ned Tijdschr Geneeskd; 2004 May; 148(21):1024-30. PubMed ID: 15185436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pervasive developmental disorders not otherwise specified. A developmental-psychopathological approach for the development of made-to-measure treatment planning.
    Verheij F; van Loon H
    Acta Paedopsychiatr; 1992; 55(4):235-42. PubMed ID: 1492555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic treatment of behavioral symptoms in autism and pervasive developmental disorders.
    Findling RL
    J Clin Psychiatry; 2005; 66 Suppl 10():26-31. PubMed ID: 16401147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How environmental and genetic factors combine to cause autism: A redox/methylation hypothesis.
    Deth R; Muratore C; Benzecry J; Power-Charnitsky VA; Waly M
    Neurotoxicology; 2008 Jan; 29(1):190-201. PubMed ID: 18031821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gold implants and increased expression of metallothionein-I/II as a novel hypothesized therapeutic approach for autism.
    Ghanizadeh A
    Toxicology; 2011 Apr; 283(1):63-4. PubMed ID: 21335051
    [No Abstract]   [Full Text] [Related]  

  • 11. Childhood autism: a circuit syndrome?
    Lee DA; Lopez-Alberola R; Bhattacharjee M
    Neurologist; 2003 Mar; 9(2):99-109. PubMed ID: 12808372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autism spectrum disorder-associated biomarkers for case evaluation and management by clinical geneticists.
    Geier DA; Geier MR
    Expert Rev Mol Diagn; 2008 Nov; 8(6):671-4. PubMed ID: 18999918
    [No Abstract]   [Full Text] [Related]  

  • 13. Animal model of autism using GSTM1 knockout mice and early post-natal sodium valproate treatment.
    Yochum CL; Bhattacharya P; Patti L; Mirochnitchenko O; Wagner GC
    Behav Brain Res; 2010 Jul; 210(2):202-10. PubMed ID: 20178820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder.
    Sandler AD; Sutton KA; DeWeese J; Girardi MA; Sheppard V; Bodfish JW
    N Engl J Med; 1999 Dec; 341(24):1801-6. PubMed ID: 10588965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological treatment options for autism spectrum disorders in children and adolescents.
    Leskovec TJ; Rowles BM; Findling RL
    Harv Rev Psychiatry; 2008; 16(2):97-112. PubMed ID: 18415882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxidative stress in autism: increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin--the antioxidant proteins.
    Chauhan A; Chauhan V; Brown WT; Cohen I
    Life Sci; 2004 Oct; 75(21):2539-49. PubMed ID: 15363659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Autism of unknown aetiology].
    Holguín JA
    Rev Neurol; 2003 Aug 1-15; 37(3):259-66. PubMed ID: 12938058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autism: a target of pharmacotherapies?
    Gerlai R; Gerlai J
    Drug Discov Today; 2004 Apr; 9(8):366-74. PubMed ID: 15081964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered vascular phenotype in autism: correlation with oxidative stress.
    Yao Y; Walsh WJ; McGinnis WR; Praticò D
    Arch Neurol; 2006 Aug; 63(8):1161-4. PubMed ID: 16908745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autism spectrum disorders: emerging pharmacotherapy.
    Bostic JQ; King BH
    Expert Opin Emerg Drugs; 2005 Aug; 10(3):521-36. PubMed ID: 16083327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.